| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
5 companies
Fust Matthew K is a Director at RARE, with reported holdings spanning 5 companies. Recent filings cover 0 purchases and 25 sales. Those positions are worth an estimated $187K at current prices.
Our model assigns Fust Matthew K a strong insider score of 77/100, based on 12 past trades. Over a 12-month horizon, 81.8% of those trades were profitable, with an average 12-month return of +31.0%.
Fust Matthew K's largest disclosed position is in NMRA as Director, worth about $177K. The recent filings there lean toward selling, a net 21,788 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 16,000 | $44.75 | $716,000.00 | -41.2% | +4.5% | - | |
| Oct 18, 2024 | NMRA Neumora Therapeutics, Inc. | Director | Sale+OE10b5-1 | 21,788 | $17.03 | $370,961.81 | -52.0% | -86.8% | -89.5% | |
| Mar 20, 2024 | CRNX Crinetics Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 60,000 | $44.14 | $2,648,150.00 | -76.4% | -2.6% | -24.5% | |
| Mar 7, 2024 | RARE Ultragenyx Pharmaceutical Inc. | Director | Sell10b5-1 | 12,195 | $50.88 | $620,442.75 | -45.1% | -18.5% | -24.1% | |
| Jul 13, 2022 | CRNX Crinetics Pharmaceuticals, Inc. | Director | Sale+OE | 5,700 | $20.96 | $119,454.90 | -31.3% | -20.8% | -6.0% | |
| Nov 4, 2021 | ATRA Atara Biotherapeutics, Inc. | Director | Sell | 13,354 | $19.50 | $260,403.00 | -29.8% | -25.8% | -76.1% | |
| Nov 1, 2021 | CRNX Crinetics Pharmaceuticals, Inc. | Director | Sale+OE | 8,954 | $25.50 | $228,327.00 | -41.7% | -29.9% | -31.3% | |
| Sep 8, 2021 | CRNX Crinetics Pharmaceuticals, Inc. | Director | Sale+OE | 6,046 | $25.50 | $154,173.00 | -32.5% | +8.0% | -13.9% | |
| Jul 26, 2021 | CRNX Crinetics Pharmaceuticals, Inc. | Director | Sale+OE | 5,000 | $19.59 | $97,950.00 | -28.5% | +17.9% | +11.7% | |
| Jul 19, 2021 | CRNX Crinetics Pharmaceuticals, Inc. | Director | Sale+OE | 5,000 | $19.50 | $97,500.00 | -28.5% | -0.6% | +4.6% |